Table 1.
Patient Characteristics
| Mean, Number, or Median (Interquartile Range) | Mean, Number, or Median (Interquartile Range) | ||
|---|---|---|---|
| Age (yr) | 70.4 ± 8.4 | TP (g/dl) | 7.1 ± 0.5 |
| Male/Female | 214/10 | T. Bil (mg/dl) | 0.74 ± 0.31 |
| BMI (kg/m2) | 22.7 ± 3.4 | AST (U/l) | 23.0 ± 8.3 |
| Follow-up period (yr) | 4.58 (2.91–6.25) | ALT (U/l) | 21.6 ± 11.2 |
| Lung cancer onset (%/yr) | 1.85 | LDH (U/l) | 197.4 ± 40.3 |
| Pack-years | 50.7 ± 31.6 | BUN (mg/dl) | 16.9 ± 5.2 |
| Current smoker (%) | 12.9 | Cr (mg/dl) | 0.83 ± 0.24 |
| Death (%) | 8.0 | eGFR (mL/min/1.73 m2) | 74.7 ± 19.7 |
| Survival period (days) | 1671 (1062 −2282) | UA (mg/dl) | 5.9 ± 1.4 |
| CAT (score) | 9.6 ± 7.3 | Na (mEq/l) | 141.3 ± 2.3 |
| LAA (score) | 5.2 ± 4.1 | K (mEq/l) | 4.3 ± 0.4 |
| Change in LAA (score) | 0.0 (0.0–0.5) | Cl (mEq/l) | 104.7 ± 2.6 |
| Exacerbations (/yr) | 0.00 (0.00–0.16) | WBC (/μL) | 6384.4 ± 1960.7 |
| GOLD I/II/III/IV | 73/108/33/10 | Neut (/μL) | 3830.1 ± 1470.1 |
| GOLD A/B/C/D | 124/87/5/8 | Lymph (/μL) | 1816.9 ± 685.3 |
| FVC (L) | 3.25 ± 0.77 | Mono (/μL) | 392.8 ± 142.1 |
| FEV1 (L) | 1.88 ± 0.64 | Eos (/μL) | 170.0 (100.0–260.0) |
| %FEV1 (%) | 68.4 ± 20.4 | Baso (/μL) | 41.7 ± 23.4 |
| Changes in FEV1 (mL/yr) | −14.0 (−52.0–15.0) | RBC (106/μL) | 4.57 ± 0.53 |
| Changes in %FEV1 (%/yr) | 0.112 (−1.177–1.375) | Hb (g/dl) | 14.0 ± 1.6 |
| Bronchodilator reversibility (%) | 15.8 | Ht (%) | 42.9 ± 4.3 |
| FeNO (ppb) | 32.4 ± 24.2 | Plt (104/μL) | 22.2 ± 6.9 |
| Use of LAMA (%) | 23.2 | IgE (IU/mL) | 70.0 (23.8–236.0) |
| Use of LABA (%) | 20.1 | Fe (μg/dl) | 93.9 ± 38.7 |
| Use of ICS at enrollment (%) | 11.2 | Fer (ng/mL) | 94.0 (44.0–169.8) |
| Use of ICS during follow-up period (%) | 29.9 | hsCRP (mg/dl) | 0.09 (0.04–0.21) |
| ACO (%) | 13.8 | D-dimer (μg/dl) | 0.83 (0.54–1.39) |
| Interstitial pneumonia (%) | 7.6 | Fib (mg/dl) | 329.0 ± 77.5 |
| CPFE (%) | 5.8 | 5-HIAA (ng/mL) | 5.8 (4.6–8.5) |
| ACE (U/L) | 12.8 (10.0–15.5) | ||
| TARC (pg/mL) | 384.9 ± 226.5 | ||
| Hcy (nmol/mL) | 11.4 ± 5.1 | ||
| PRA (ng/mL/hr) | 1.2 (0.7–2.1) |
Note: Data are presented as mean ± SD, median (with ranges in parentheses, 25th–75th percentile) or n.
Abbreviations: BMI, body mass index; CAT, COPD assessment score; LAA, low attenuation area on CT scan; FeNO, fractional exhaled nitric oxide; LAMA, long-acting muscarinic antagonist; LABA, long-acting β2 agonist; ICS, inhaled corticosteroid; ACO, asthma-COPD overlap; CPFE, combined pulmonary fibrosis and emphysema; IgE, immunoglobulin E; Fer, ferritin; hsCRP, high-sensitivity C-reactive protein; Fib, fibrinogen; 5-HIAA, 5-hydroxyindoleacetic acid; TARC, thymus and activation-regulated chemokine; Hcy, homocysteine; PRA, plasma renin activity.